Safety of and antibody response to the BNT162b2 COVID-19 vaccine in adolescents and young adults with underlying disease
Journal of Infection and Chemotherapy
; 29(1):61-66, 2023.
Article
in English
| Scopus | ID: covidwho-2245182
ABSTRACT
Background:
Data are limited regarding the safety of and antibody response to the BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger ribonucleic acid vaccine in adolescents and young adults with underlying disease.Methods:
This prospective observational study enrolled patients age 12–25 years with chronic underlying disease who received 2 doses of BNT162b2. A 18-item questionnaire was used to assess adverse events within 7 days post-vaccination, and data regarding severe adverse events were collected from electronic medical records. An antibody titer for the receptor-binding domain of the spike protein in SARS-CoV-2 was used to assess antibody response after the second vaccine dose.Results:
Study participants were 429 patients (241 [56.2%] age 12–15 years;188 [43.8%] age 16–25 years). The most common underlying diseases were genetic or chromosomal abnormalities and/or congenital anomalies, followed by endocrine or metabolic diseases;32% of participants were immunocompromised. Severe adverse events were observed after the second dose in 1 (0.4%) patient age 12–15 years and in 2 (1.1%) patients age 16–25 years;all patients recovered. Seropositivity after the second vaccine dose was 99.0%. The geometric mean antibody titer was higher in patients age 12–15 years versus 16–25 years (1603.3 [1321.8–1944.7] U/mL vs. 949.4 [744.2–1211.0] U/mL). Compared with immunocompetent patients, immunocompromised patients had a lower antibody titer (2106.8 [1917.5–2314.7] U/mL vs. 467.9 [324.4–674.8] U/mL).Conclusions:
Vaccination with BNT162b2 was acceptably safe and immunogenic for adolescents and young adults with underlying disease. © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
Adolescent; Adult; Antibodies, Viral; Antibody Formation; BNT162 Vaccine; Child; COVID-19; COVID-19 Vaccines; Humans; SARS-CoV-2; Young Adult; biological product; bnt 162b 2; immunosuppressive agent; steroid; tozinameran; virus spike protein; virus antibody; anaphylaxis; antibody response; antibody titer; arthralgia; Article; bloody diarrhea; chill; chromosome aberration; congenital malformation; controlled study; coronavirus disease 2019; drug safety; electronic medical record; endocrine disease; face pain; fatigue; female; fever; genetic disorder; headache; human; immunocompromised patient; major clinical study; male; metabolic disorder; myalgia; observational study; prospective study; questionnaire; receptor binding; thorax pain; vaccination; vomiting; adverse event; antibody production; prevention and control; Immunization; mRNA
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Topics:
Vaccines
Language:
English
Journal:
Journal of Infection and Chemotherapy
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS